Fujian Province 4 plus 7 renewal results out of the lipeone not flow standard

On May 22, the Fujian Provincial Health Insurance Bureau issued a notice on the implementation of the "4 plus 7" pilot agreement due to follow-up related work, the results of the election from May 29 on the procurement platform on the network implementationFrom June 1st, the same drug and the same non-selected drug will simultaneously implement the prescribed maximum sales price and differentiated medical insurance payment standardsThe original selected drug, which failed to renew the contract, is given a six-month transition period at the selected priceamong them, atoflavatin, Ntokavir dispersal tablets, onitrogen flats, cephalosporine tablets, gifitin tablets, Fusimpli sodium tablets, montoxel 7 varieties to replace the selected enterpriseThe specific replacement content is as follows:notice pointed out that the renewal work should do a good job of smooth docking, some of the original selected enterprises this time failed to successfully renew the varieties, medical institutions to develop a smooth transition program, according to the actual situation of patients classification policy, in order to ensure the completion of the procurement of selected drugs under the premise of reasonable protection of the continuity of drug useIf the original selected drug that fails to renew the contract can continue to guarantee the supply according to the "4 plus 7" pilot price, the medical insurance payment standard for the relevant drugs during the transition period may continue to be determined according to the original selected priceLipeketone tablets because in the public inquiry when no enterprise should bid, in turn to the expansion of the price from low to high ranked second and third in the enterprise according to the enterprise expansion of the selected price, Huahai Pharmaceutical spree finally with 7.2 yuan / box price successfully won the bidSo far, Huahai Pharmaceuticals has successfully won the renewal of all 11 cities